Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839586 | 0.82 | PTGS1 (0.36) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL4468860 | 0.78 | PTGS1 (0.34) | MEN1KMT2APTGS1PTGS2CYP1A2 | |
| SCHEMBL10969688 | 0.77 | PTGS1 (0.31) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5268517 | 0.74 | PTGS1 (0.32) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL6679401 | 0.74 | PTGS1 (0.32) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5267755 | 0.71 | AKT1 (0.34) | MEN1KMT2A | |
| SCHEMBL5839654 | 0.70 | PTGS1 (0.37) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL5268555 | 0.69 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL6982911 | 0.68 | CYP3A4 (0.50) | MEN1KMT2APTGS1PTGS2CYP1A2 | |
| SCHEMBL13592378 | 0.68 | ALOX5 (0.39) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856040-A2 | NOVEL LIPOXYGENASE INHIBITORS | Eli Lilly and Company (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006093547-A2 | NOVEL LIPOXYGENASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-09-08 | — | — | WO | claimed |
| US-20060193797-A1 | Chroman derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC | 2006-08-31 | — | — | US | claimed |
| CN-101128423-A | Novel lipoxygenase inhibitors | LILLY CO ELI (US) | 2008-02-20 | — | — | CN | disclosed |
| EP-1856040-A2 | NOVEL LIPOXYGENASE INHIBITORS | Eli Lilly and Company (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006093547-A2 | NOVEL LIPOXYGENASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060193797-A1 | Chroman derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193797-A1 | Chroman derivatives as lipoxygenase inhibitors | NR0B1, ALOX5, ALOX15B | MEN1 4700/4885KMT2A 4171/4885PTGS1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.